---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003013"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:34:19.396591+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics closes $33.1M convertible note, increases authorized shares to 260M

## Summary
- Issued $33.1M convertible note to Avondale Capital on March 13, 2025; proceeds used to repay $32.91M Streeterville note.
- Stockholders approved increase in authorized common shares from 60M to 260M, effective March 11.
- Annual Meeting elected directors: Julian Gangolli, Ralph Thurman, Lawrence Kenyon to Class III.
- Stockholders approved potential issuance of >19.99% of outstanding common stock upon note conversion.
- Ratified KPMG as auditor for FY2025; advisory say-on-pay passed.

## SEC filing metadata
- accession: 0001558370-25-003013
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/0001558370-25-003013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/otlk-20250311x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003013
- JSON: https://secwatch.observer/filing/0001558370-25-003013.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.